Nio (NYSE:NIO) has shifted into turbo drive Thursday, but some investors might question whether shares have gas left in the tank. Let's take a look at what's happening with Nio stock to determine a risk-adjusted solution to better navigate its thrilling ride up today.Source: Sundry Photography / Shutterstock.com The market is offering investors some pre-July 4 fireworks to finish off the abbreviated workweek. The SPDR S&P Mid-Cap 400 ETF (NYSEARCA:MDY) is up 2.25% on much stronger-than-forecast monthly jobs data. The index, however, is still struggling inside a trading range more than a month in-the-making after a historic bull-run from March's corrective bottom.But that's not stopping recently crowned mid-cap Nio, whose shares continue to trade aggressively higher.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNIO stock is up nearly 17% Thursday and leading its market-weighted peers to fresh relative highs. And those gains come on top of a near 100% return...
When it comes to biotech companies, I am not surprised why many investors feel they are playing Russian roulette. Names that were obscure before the novel coronavirus are suddenly on a bull run for every biotech firm involved in coming up with a commercial vaccine. Hence, until we have a vaccine, iBio (NYSEMKT:IBIO) stock will continue to ascend higher with each positive news report.Source: Shutterstock Shares of the company increased by about 600% year to date, and I don't expect the momentum to stop anytime soon.At the same time, a lot of hype surrounding the stock is unwarranted. As I mentioned in my previous piece, the company does not have a successful track record of producing vaccines to treat illnesses. This fact makes me wary of committing a large amount of capital to the firm.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Utilities Stocks to Buy With...
Editor's note: This article is part of InvestorPlace.com's Best Stocks for 2020 contest. Eric Fry's pick for the contest is Freeport-McMoRan (NYSE:FCX).When we last discussed Freeport-McMoRan (NYSE:FCX), the novel coronavirus pandemic was in full force, the U.S. stock market was struggling to recover from a wicked 34% drop and copper prices had tumbled to a three-year low.This toxic cocktail hammered Freeport's share price from a February high near $13 to a March low below $5. That moment offered plenty of cause for concern … but not for all-out panic.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs I stated at the time:Yes, the coronavirus epidemic will depress economic activity short term, which will depress copper demand short term…Despite that frightening prospect, I expect FCX stock to recover and deliver a solid gain for 2020…Freeport's decimated share price discounts most of [the risks]. It does not price in any potential upside.The...
At the beginning of the week, DocuSign (NASDAQ:DOCU) stock saw its share price decline. Investors looked at economic reopening across the U.S. as a negative for the firm's future performance. DocuSign specializes in orchestrating contracts online and is best-known for its eSignature service, which allows people to sign contracts electronically. Source: Sundry Photography / Shutterstock.com When the novel coronavirus struck and forced people to work from home and limit social contact, DocuSign stock was one of the first companies investors turned to. With businesses around the country shifting their entire operation online, the ability to close contracts without face-to-face travel was essential.But now that it seems things could get back to normal, investors are tentative. While some might be taking profits on DOCU stock now, patience could pay off big time for long-term investors, as DocuSign looks likely to continue flourishing even beyond the pandemic.InvestorPlace - Stock Market News, Stock Advice...
If you are looking for the best ideas for your portfolio you may want to consider some of Ensemble Capital's top stock picks. Ensemble Capital, an investment management firm, is bearish on Oracle Corp (NYSE:ORCL) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its investment […]...
